Toxicity of exposure to binary mixtures of four anti-neoplastic drugs in Daphnia magna and Ceriodaphnia dubia

Aquatic Toxicology

Volumn 157, Issue , 2014, Pages 41-46

  Parrella, Alfredo ^a   Kundi, Michael ^b   Lavorgna, Margherita ^a   Criscuolo, Emma ^a   Russo, Chiara ^a   Isidori, Marina ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Medical University of Vienna   (Austria)

Author keywords

Anti neoplastic drugs; Chronic toxicity; Crustaceans; Effluents; Mixtures

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; IMATINIB; ANTINEOPLASTIC AGENT; WATER POLLUTANT;

DNA; DRUG; ECOLOGICAL IMPACT; ECOTOXICOLOGY; EFFLUENT; ENVIRONMENTAL IMPACT; FISH; FRESHWATER ECOSYSTEM; PHYLOGENETICS; POLLUTION EXPOSURE; TOXICITY TEST;

ANIMAL EXPERIMENT; AQUATIC ENVIRONMENT; ARTICLE; CERIODAPHNIA DUBIA; CHRONIC TOXICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DAPHNIA MAGNA; DRUG MIXTURE; ECOTOXICITY; ENVIRONMENTAL EXPOSURE; NONHUMAN; PHYSICAL CHEMISTRY; ANALYSIS OF VARIANCE; ANIMAL; CLADOCERA; DAPHNIA; DRUG EFFECTS; DRUG POTENTIATION; TOXICITY; WATER POLLUTANT;

CERIODAPHNIA DUBIA; CRUSTACEA; DAPHNIA MAGNA;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; CLADOCERA; DAPHNIA; DRUG SYNERGISM; WATER POLLUTANTS, CHEMICAL;

EID: 84908111562     PISSN: 0166445X     EISSN: 18791514     Source Type: Journal    
DOI: 10.1016/j.aquatox.2014.09.012     Document Type: Article

References (32)

1. Besse J.P., Latour J.F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ. Int. 2012, 39:73-86.
2. Brezovšek P., Eleršek T., Filipič M. Toxicities of four anti-neoplastic drugs and their binary mixtures tested on the green alga Pseudokirchneriella subcapitata and the cyanobacterium Synechococcus leopoliensis. Water Res. 2014, 52:168-177.
3. Caldwell D.J., Mastrocco F., Margiotta-Casaluci L., Brooks B.W. An integrated approach for prioritizing pharmaceuticals found in the environment for risk assessment, monitoring and advanced research. Chemosphere 2014, 10.1016/j.chemosphere.2014.01.021.
4. Constantine L.A., Huggett D.B. A comparison of the chronic effects of human pharmaceuticals on two cladocerans, Daphnia magna and Ceriodaphnia dubia. Chemosphere 2010, 80:1069-1074. 10.1016/j.chemosphere.2014.01.013.
5. Fent K., Escher C., Caminada D. Estrogenic activity of pharmaceuticals and pharmaceutical mixtures in a yeast reporter gene system. Reprod. Toxicol. 2006, 22:175-185.
6. Galus M., Jeyaranjaan J., Smith E., Li H., Metcalfe C., Wilson J.Y. Chronic effects of exposure to a pharmaceutical mixture and municipal wastewater in zebrafish. Aquat. Toxicol. 2013, 132-133:212-222.
7. Greco W., Unkelbach H.D., Pöch G., Sühnel J., Kundi M., Bödeker W. Consensus on concepts and terminology for combined-action assessment: the Saariselkä agreement. Arch. Complex Environ. Stud. 1992, 4(3):65-69.
8. ISO 10706 Water Quality-Determination of Long Term Toxicity of Substances to Daphnia magna Straus (Cladocera, Crustacean) 2000, International Organization for Standardization, Geneva, Switzerland.
9. ISO 20665 Water Quality-Determination of Chronic Toxicity to Ceriodaphnia dubia in 7 Days-Population Growth Inhibition Test 2008, International Organization for Standardization, Geneva, Switzerland.
10. Jha A.N. Ecotoxicological applications and significance of the comet assay. Mutagenesis 2008, 23(3):207-221.
11. Jia J., Zhu F., Ma X., Cao Z.W., Li Y.X., Chen Y.Z. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8:111-128.
12. Katsnelson B.A., Privalova L.I., Varaksin A.N., Kazmer J.I., Kireyeva E.P., Panov V.G. An approach to characterizing the type of combined environmental toxicity based on epidemiologically assessed exposure-response relationships. Open Epidemiol. J. 2011, 4:60-69.
13. Kosjek T., Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. Trends Anal. Chem. 2011, 30:1065-1087.
14. Kosjek T., Perko S., Žigon D., Heath E. Fluorouracil in the environment: analysis, occurrence, degradation and transformation. J. Chromatogr. A. 2013, 1290:62-72.
15. Kovalova L., McArdell C.S., Hollender J. Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry. J. Chromatogr. A 2009, 1216:1100-1108.
16. Kübler H.R., van Randenborgh H., Treiber U., Wutzler S., Battistel C., Lehmer A., Wagenpfeil S., Hartung R., Paul R. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 2005, 63(4):385-394.
17. Kümmer K., Schuster A., Haiss A., Günther A., Jacobs J., Mohring S., Hamsher G., Simon D. Umweltrisikobewertung von Zytostatika 2009, Umweltbundesamt, f. UBA-FB001256, Dessau-Roßlau.
18. Kümmerer K. The presence of pharmaceuticals in the environment due to human use - present knowledge and future challenges. J. Environ. Manage. 2009, 90:2354-2366.
19. Lenz K., Mahnik S.N., Weissenbacher N., Mader R.M., Krenn P., Hann S., Koellensperger G., Uhl M., Knasmueller S., Ferk F., Bursh W., Fuerhacker M. Monitoring, removal and risk assessment of cytostatic drugs in hospital wastewater. Water Sci. Technol. 2007, 56(12):141-149.
20. Mahnik S.N., Rizovski B., Fürhacker M., Mader R.M. Determination of 5-fluorouracil in hospital effluents. Anal. Bioanal. Chem. 2004, 380:31-35.
21. Mahnik S.N., Lenz K., Weissenbacher N., Mader R.M., Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007, 65(1):30-37.
22. Negreira N., López de Alda M., Barceló D. On-line solid phase extraction-liquid chromatography-tandem mass spectrometry for the determination of 17 cytostatics and metabolites in waste, surface and ground water samples. J. Chromatogr. A 2013, 1280:64-74.
23. OECD 211 Daphnia Magna Reproduction Test 2008, Organization for Economic Co-operation and Development, Paris.
24. Parrella A., Lavorgna M., Criscuolo E., Russo C., Fiumano V., Isidori M. Acute and chronic toxicity of six anticancer drugs on rotifers and crustaceans. Chemosphere 2014, 115:59-66.
25. Pichler C., Filipič M., Kundi M., Rainer B., Knasmueller S., Mišík M. Assessment of genotoxicity and acute toxic effect of the imatinib mesylate in plant bioassays. Chemosphere 2014, 10.1016/j.chemosphere.2014.01.010.
26. Shi S., Yao W., Xu J., Long J., Liu C., Yu X. Combinational therapy: new hope for pancreatic cancer?. Cancer Lett. 2012, 317(2):127-135.
27. Statsoft Inc., 2011. STATISTICA (data analysis software system), ver. 10.0. Statsoft Inc.ed., Tulsa, OK, USA.
28. Tallarida R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 2006, 319(1):1-7.
29. Toolaram A.P., Kümmerer K., Schneider M. Environmental risk assessment of anti-cancer drugs and their transformation products: a focus on their genotoxicity characterization-state of knowledge and short comings. Mutat. Res. 2014, 10.1016/j.mrrev.2014.02.001.
30. Wozniak K., Czechowska A., Blasiak J. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chem. Biol. Interact. 2004, 147(3):309-318.
31. Xie H. Occurrence, ecotoxicology, and treatment of anticancer agents as water contaminants. J. Environ. Anal. Toxicol. 2012, S2:1-11.
32. Zhang J., Chang V.W.C., Giannis A., Wang J.Y. Removal of cytostatic drugs from aquatic environment: a review. Sci. Total Environ. 2013, 445-446:281-298.